Real-world implementation of pertuzumab from 2013 to 2023 for de Novo HER2-positive metastatic breast cancer in the Netherlands: a population-based study
Authors:
- Nan DingNDNan Ding
- Sandra M.E. GeurtsSGSandra M.E. Geurts
- Ingeborg J.H. VriensIVIngeborg J.H. Vriens
- Renée VissermanRVRenée Visserman
- Thiemo J.A. van NijnattenTNThiemo J.A. van Nijnatten
- Marjolein SmidtMSMarjolein Smidt
- Adri C. VoogdAVAdri C. Voogd
- Janneke VerloopJVJanneke Verloop
- Vivianne C.G. Tjan-HeijnenVTVivianne C.G. Tjan-Heijnen
Open Access
- 25 July 2026
- journal article
- Published by Elsevier in The Breast
- Vol. 89
Abstract
No abstract availableThis publication has 40 references indexed in Scilit:
- Real‐world comparative effectiveness and safety of Pertuzumab in patients with HER2+ metastatic breast cancer: A pan‐Canadian population‐based cohort studyInternational Journal of Cancer, 2025
- Comorbidity influence in observational studies: Why ignore the real world?Pharmacoepidemiology and Drug Safety, 2024
- Clinical subtype, treatment response, and survival in De Novo and recurrent metastatic breast cancerBreast Cancer Research and Treatment, 2022
- Practice Patterns and Outcomes of Novel Targeted Agents for the Treatment of ERBB2-Positive Metastatic Breast CancerJAMA Oncology, 2021
- Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE RegistryBreast Cancer Research and Treatment, 2021
- Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registryBreast Cancer Research and Treatment, 2021
- Comparison of outcomes in a population-based cohort of metastatic breast cancer patients receiving anti-HER2 therapy with clinical trial outcomesBreast Cancer Research and Treatment, 2020
- Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)Breast Cancer Research and Treatment, 2013
- Socioeconomic differences in survival among breast cancer patients in the Netherlands not explained by tumor sizeBreast Cancer Research and Treatment, 2010
- What's the Relative Risk?JAMA, 1998